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Introduction {#s1}
============

Breast cancer continues to be a major public health problem all over the world. The American Cancer Society estimates that there will be about 296,980 new cases of breast cancer in 2013, which is expected to account for 14% of female cancer deaths.

A realistic strategy for the reduction of breast cancer mortality rates and timely treatment is to detect the disease while it is still in an early stage.[@pone.0108349-Panel1], [@pone.0108349-Buscombe1]. The most common screening method for early breast cancer is mammography, which is very sensitive in the detection of malignant breast disease. However in several groups of breast cancer patients, including those with fibroadenoma breasts, post implants, mastectomy or severe dysplasia, mammography has a low predictive value (20%--30%) and is not accurate, requiring patients to undergo histopathological examinations for a definitive diagnosis [@pone.0108349-Kopans1], [@pone.0108349-Murphy1]. To improve diagnostic accuracy, new methods are being studied as alternatives to mammography. Over the last twenty years, Scintimammography (SMM) has been introduced as an adjunct modality to present imaging modalities for breast cancer imaging [@pone.0108349-Schillaci1]. In addition to the imaging modality, several radiopharmaceuticals have also been investigated for diagnostic imaging procedures in patients with suspected breast cancer [@pone.0108349-Liberman1]. ^18^F-fluorodeoxyglucose (FDG) positron emission tomography (PET) [@pone.0108349-Soussan1] is proven to be the most effective in detection of breast cancer for diagnosis, staging and restaging, but its use is limited by the high cost of equipment and lack of general availability, especially in developing countries. Alternatively, single photon emission computed tomography (SPECT) is more widely used with a much lower cost worldwide.

^99m^Tc-methoxyisobutylisonitrile (^99m^Tc-MIBI) is an important tracer for oncological applications and has been widely used in breast tumor imaging. However, this tracer originated from nuclear medicine for cardiac imaging and was not specifically designed for tumor imaging. The exact mechanism of uptake in breast cancer cells is still not entirely clear. It is reported that ^99m^Tc-MIBI is concentrated in cancer cells by an energy-requiring transport mechanism, specifically by transmembrane electrical potentials, as well as by non-specific mechanisms, and the tracer is stored within the mitochondria [@pone.0108349-Tiling1].

It is well documented that integrin αvβ3 plays a critical role in the regulation of tumor angiogenesis and metastasis [@pone.0108349-Hood1], [@pone.0108349-Ruoslahti1]. The integrin is upregulated on activated endothelial cells and is highly expressed in tumor cells of various tumor types, including breast cancer [@pone.0108349-Desgrosellier1], [@pone.0108349-Niu1]. Over the past decade, radiolabeled Arg-Gly-Asp (RGD) peptides and analogs that specifically target integrin αvβ3 have been intensively investigated for noninvasive imaging of tumors in pre-clinical and clinical studies [@pone.0108349-Jia1]--[@pone.0108349-Bhojani1]. We previously developed the αvβ3-specific tracer ^99m^Tc-3P-Arg-Gly-Asp (^99m^Tc-3P~4~-RGD~2~) for SPECT and already demonstrated that ^99m^Tc-3P~4~-RGD~2~ SPECT allows specific imaging of αvβ3 expression with high accuracy in detecting malignant solitary pulmonary nodules (SPNs), esophageal cancer, and malignant gliomas [@pone.0108349-Qingjie1]--[@pone.0108349-Gao2].

In this study, we compare the diagnostic value of ^99m^Tc-3P~4~-RGD~2~ SMM with ^99m^Tc-MIBI SMM for the detection of breast cancer by receiver operating characteristic (ROC) curve analysis.

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

Thirty-six patients with breast masses on physical examination and/or suspicious mammographic findings that required fine needle aspiration cytology biopsy (FNAB) were included in this study. The patient mean age was 41.9±12.2 years (age range 22--65 years. All patients were referred for ^99m^Tc-MIBI and ^99m^Tc-3P~4~-RGD~2~ SMM on an individual basis. The time interval between the two imaging procedures was 3.2±1.4 days. Finally, ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI SMM results were compared with each other and with the final histopathological diagnosis. Inclusion and exclusion criteria for entry into the study are summarized in [Table 1](#pone-0108349-t001){ref-type="table"}. This study was approved by the Ethics Committee of China-Japan Union Hospital of Jilin University. Informed written consent to participate in the SMM studies was obtained from all patients.
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###### Inclusion and exclusion criteria of study.

![](pone.0108349.t001){#pone-0108349-t001-1}

  Inclusion Criteria                                                                    Exclusion Criteria
  ------------------------------------------------------ ---------------------------------------------------------------------------------
  Female                                                                                     Pregnancy
  Not pregnant                                                                           Recurrent disease
  Suspicious lesion of the breast                                                       Pervious mastectomy
  Recommendation for excision biopsy after mammography            Fine needle aspiration within 1 week prior to scintimammography
  Informed consent from the patient                                                    Previous chemotherapy
                                                          Medically unstable patient (severe arrhythmia, heart failure or recent surgery)

Scintimammography protocol {#s2b}
--------------------------

Radiolabeling and quality control procedures for 3P~4~-RGD~2~ were performed as described previously [@pone.0108349-Qingjie1]. Both 3P~4~-RGD~2~ and MIBI (ShiHong Drug Development Center, Beijing, China) were radiolabelled with 738±86 MBq ^99m^technetium and thereafter administered via a single intravenous bolus injection in the contralateral arm to the affected breast, followed by a 10 mL saline flush. The effective radiation dose to the body of ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI were 2.89±0.34 mSv and 5.83±0.67 mSv, respectively [@pone.0108349-Guanghui1], [@pone.0108349-Mitchell1]. ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI SMM were performed at 60 min and 20 min after intravenous injection, respectively. Patients were in supine position with raised arms during imaging.

SPECT was performed using a double-head γ camera (Precedence, Philips Healthcare), equipped with low-energy parallel hole collimators. The matrix was 128×128 pixels, and the photopeak was centered at 140 keV with a symmetrical 20% window. Imaging with both radiotracers was performed using 6° angular steps in a 20 s time frame. Distance between the breast and detector was minimized.

Data analysis {#s2c}
-------------

Both ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI SMM uptake were evaluated by semiquantitative analysis. Regions of interest (ROIs) were drawn around the tumor and an area of normal breast tissue in the same breast on lateral images and used to determine the tumor to non-tumor ratios (T/NT) of ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI.

All numerical results are reported as mean values with standard deviations (SDs). Student\'s t test was used for statistical comparison of quantitative indices between the malignant and benign breast disease groups. The IBM SPSS Statistics19 software was used to determine cut-off values of quantitative indices in the detection of primary breast cancer. The incremental diagnostic value of quantitative indices analysis was performed using calculated areas under the curve (AUCs) in ROC analysis. Statistical significance was defined as p\<0.05.

Results {#s3}
=======

Samples for histological examination were obtained by surgery in 28 patients and by core needle biopsy in eight patients. Breast cancer was confirmed in 26 patients and resulted in a total of 28 cancer lesions with diameters ranging from 0.3 cm to 7.9 cm (mean ± SD: 2.86±1.73 cm). Benign breast disease was found in 10 patients with a total of 11 benign lesions ranging in diameter from 0.4 cm to 6.5 cm (mean ± SD: 2.83±1.91 cm). In this study, the yielding breast cancer prevalence was 71.8% ([Table 2](#pone-0108349-t002){ref-type="table"}).

10.1371/journal.pone.0108349.t002

###### Scintimammography results versus final histopathological diagnosis of 36 patients.

![](pone.0108349.t002){#pone-0108349-t002-2}

  Patient    Age (years)   Diameter (cm)   RGD (T/NT)   MIBI (T/NT)     Histopathological Diagnosis
  --------- ------------- --------------- ------------ ------------- ---------------------------------
  1              58             2.8           4.55         2.70               Invasive ductal
  2              43             4.2           2.81         1.90              Invasive lobular
  3              26             0.6           1.31         1.02               Invasive ductal
  4              52             3.2           3.51         1.70                    DCIS
  5              53             2.5           5.70         3.10               Invasive ductal
  6              65             1.8           3.33         1.90               Invasive ductal
  7              45             0.9           2.71         1.54               Invasive ductal
  8              59           7.9/3.0      4.24/3.32     3.51/1.85    Invasive ductal/Invasive ductal
  9              49             0.3           1.29         1.14               Invasive ductal
  10             49             1.8           2.91         1.68               Invasive ductal
  11             33             3.7           2.48         2.33               Invasive ductal
  12             23             2.5           5.04         3.65               Invasive ductal
  13             36             0.4           1.02         1.23               Invasive ductal
  14             29             6.0           8.27         4.87              Invasive lobular
  15             31             2.2           2.96         1.31                    DCIS
  16             56             4.2           3.82         2.08               Invasive ductal
  17             41             3.5           5.62         4.21              Invasive mucinous
  18             37             3.8           4.20         2.10               Invasive ductal
  19             22             4.5           2.52         1.62               Invasive ductal
  20             31           1.7/0.8      4.12/2.49     1.85/1.91         Invasive ductal/DCIS
  21             39             4.1           3.34         2.17               Invasive ductal
  22             61             1.2           3.40         3.74               Invasive ductal
  23             46             3.3           2.99         1.61              Invasive mucinous
  24             58             2.9           5.23         3.21               Invasive ductal
  25             27             2.0           3.01         1.60              Invasive lobular
  26             44             4.2           2.79         1.82               Invasive ductal
  27             41             4.3           1.11         1.34                Fibroadenoma
  28             28             2.1           4.47         2.58         Fibroadenoma with mastitis
  29             31           6.5/0.7      1.92/1.32     1.26/1.10      Fibroadenoma/ductal ectasia
  30             47             3.2           1.34         2.81                Fibroadenoma
  31             29             1.8           1.43         1.37             Fibrocystic disease
  32             54             5.2           2.31         1.22                Fibroadenoma
  33             49             3.3           1.1          1.09                Fibroadenoma
  34             37             1.2           1.85         1.69                Fibroadenoma
  35             25             2.4           2.17         1.02             Fibrocystic disease
  36             55             0.4           1.08         1.17               Ductal ectasia

DCIS: ductal carcinoma in situ.

We observed high ^99m^Tc-3P~4~-RGD~2~ uptake in breast cancer and low ^99m^Tc-3P~4~-RGD~2~ uptake in benign lesions ([Fig. 1A](#pone-0108349-g001){ref-type="fig"}). In ^99m^Tc-3P~4~-RGD~2~ SMM, the T/NT of breast cancer was 3.54±1.51 and that of benign lesions was 1.83±0.98. The difference was statistically significant (p\<0.001). Similarly in ^99m^Tc-MIBI SMM, high MIBI uptake was observed in breast cancer while low MIBI uptake was detected in benign lesions ([Fig. 1B](#pone-0108349-g001){ref-type="fig"}). The T/NT of breast cancer was 2.86±0.99 and that of benign lesions was 1.51±0.61. The difference was statistically significant (p\<0.001).

![T/NT for ^99m^Tc-RGD and ^99m^Tc-MIBI in malignant and benign tumors.\
(A) The T/NT for ^99m^Tc-RGD in breast cancer was significantly higher than that in benign lesions (p\<0.001). (B) The T/NT for ^99m^Tc-MIBI in breast cancer was significantly higher than that in benign lesions (p\<0.001).](pone.0108349.g001){#pone-0108349-g001}

^99m^Tc-3P~4~-RGD~2~ SMM was false negative in 3 breast cancer of invasive ductal which was the same as ^99m^Tc-MIBI SMM. The tumor size was 0.6 cm or smaller in the long axis diameter. One patient with ductal carcinoma in situ (DCIS) in the long axis diameter of 2.2 cm was clear detected by ^99m^Tc-3P~4~-RGD~2~ SMM, but not with ^99m^Tc-MIBI SMM ([Fig. 2](#pone-0108349-g002){ref-type="fig"}). ^99m^Tc-MIBI SMM was false positive in 3 benign lesions. Of the false positive cases, two were fibroadenoma and one was fibroadenoma with mastitis. The fibroadenoma with mastitis was also false positive in ^99m^Tc-3P~4~-RGD~2~ SMM ([Fig. 3](#pone-0108349-g003){ref-type="fig"}).

![A 2.2 cm ductal carcinoma in situ of the right breast in a 31-year-old woman (Patient 15).\
(A) CT scan demonstrates a mass in the right breast. (B) ^99m^Tc-3P~4~-RGD~2~ SMM demonstrates focal uptake of ^99m^Tc-3P~4~-RGD~2~ in the tumor (T/NT = 2.96). (C) ^99m^Tc-MIBI SMM demonstrates low uptake of ^99m^Tc-MIBI in the tumor (T/NT = 1.31).](pone.0108349.g002){#pone-0108349-g002}

![A 3.2 cm fibroadenoma of the left breast in a 47-year-old woman (Patient 30).\
(A) CT scan demonstrates a mass in the left breast. (B) ^99m^Tc-3P~4~-RGD~2~ SMM demonstrates low uptake of ^99m^Tc-3P~4~-RGD~2~ in the tumor (T/NT = 1.34). (C) ^99m^Tc-MIBI SMM demonstrates focal uptake of ^99m^Tc-MIBI in the tumor (T/NT = 2.81).](pone.0108349.g003){#pone-0108349-g003}

ROC analyses were performed to determine the optimal cut-off values of both ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI SMM T/NT for the detection of malignant breast cancer. When a cut-off value was used based on the ROC analysis, the sensitivity, specificity and accuracy of ^99m^Tc-3P~4~-RGD~2~ SMM were 89.3%, 90.9% and 89.7%, respectively (cutoff = 2.40 of T/NT), and those of ^99m^Tc-MIBI SMM were 87.5%, 72.7% and 82.1%, respectively (cutoff = 1.46 of T/NT). The empirical ROC areas, which estimate the overall diagnostic performance, did not differ significantly among the two diagnostic analyses ([Fig. 4](#pone-0108349-g004){ref-type="fig"}). The value was 0.851 for ^99m^Tc-3P~4~-RGD~2~ SMM and 0.781 for ^99m^Tc-MIBI SMM.

![Comparison the sensitivity and specificity of ^99m^Tc-3P~4~-RGD~2~ SMM and ^99m^Tc-MIBI SMM.\
Comparison between ^99m^Tc-3P~4~-RGD~2~ SMM and ^99m^Tc-MIBI SMM in the differential diagnosis of breast cancer and benign lesions using ROC analysis (solid line: ^99m^Tc-3P~4~-RGD~2~ SMM, dashed line: ^99m^Tc-MIBI SMM). The area under the curve of both ^99m^Tc-3P~4~-RGD~2~ SMM and ^99m^Tc-MIBI SMM are 0.851 and 0.781, respectively. The difference was not significant.](pone.0108349.g004){#pone-0108349-g004}

Discussion {#s4}
==========

Over the last twenty years, SMM has been proposed to be a complementary tool to mammography in the diagnosis of primary breast cancer [@pone.0108349-Schillaci1]. An already widely used radiopharmaceutical, ^99m^Tc-MIBI appears to be a suitable SMM scanning agent. Many publications have reported favorable sensitivity and specificity results, 84%--96% and 72%--94%, respectively, for ^99m^Tc-MIBI scintigraphy in the diagnosis of breast cancer [@pone.0108349-Burak1]--[@pone.0108349-Waxman1]. ^99m^Tc-3P~4~-RGD~2~ is a new agent with a high affinity for the αvβ3 integrin, a receptor associated with angiogenesis. In our previous study, we found that ^99m^Tc-3P~4~-RGD~2~ could accumulate in a variety of malignant lesions [@pone.0108349-Qingjie1]--[@pone.0108349-Gao2]. However, a comparative study between ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI SMM has not been previously reported.

In this present study, to differentiate benign from malignant lesions, ROC analyses were performed to determine the optimal cut-off values of T/NT of ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI SMM. When T/NT of 2.40 was used as a cut-off point, the sensitivity, specificity and accuracy of ^99m^Tc-3P~4~-RGD~2~ SMM were 89.3%, 90.9% and 89.7%, respectively. With a T/NT of 1.45 as a cut-off value, the same findings were 87.5%, 72.7% and 82.1% in ^99m^Tc-MIBI SMM, respectively. The sensitivities reported in this study for ^99m^Tc-3P~4~-RGD~2~ SMM are comparable with our previous reports; however the specificity is slightly higher than previous studies, which may be due to the low total number of benign breast lesions [@pone.0108349-Qingjie1]--[@pone.0108349-Gao2]. For ^99m^Tc-MIBI SMM, the results reported here are comparable with those in previous studies [@pone.0108349-Burak1]--[@pone.0108349-Waxman1]. Although the sensitivity, specificity and accuracy of ^99m^Tc-3P~4~-RGD~2~ SMM was slightly superior to that of ^99m^Tc-MIBI SMM in this study, the difference was not statistically significant. The area under the curve of ^99m^Tc-3P~4~-RGD~2~ SMM was slightly larger than that of ^99m^Tc-MIBI SMM, although this difference was also not significant.

It is generally accepted that the detection sensitivity of SMM is much lower for small breast cancer lesions with a diameter less than 1 cm over larger lesions [@pone.0108349-Palmedo1]. Data from a multicentre European study showed a sensitivity of 26%--56% for lesions less than 1 cm [@pone.0108349-Scopinaro1]. Similarly in the present study, neither ^99m^Tc-3P~4~-RGD~2~ nor ^99m^Tc-MIBI was sufficient to visualize tumors in three patients having malignant lesions with diameters at 0.3 cm, 0.4 cm and 0.6 cm, respectively. The ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI uptake in small lesions is considered to be underestimated due to partial volume effects from the relatively low spatial resolution of the SPECT device, though other factors such as the degree of radiopharmaceutical uptake by tumors and normal breast tissue may have contributed as well.

In one case of DCIS with a long axis diameter of 2.2 cm was false negative on ^99m^Tc-MIBI SMM but not ^99m^Tc-3P~4~-RGD~2~ SMM. Some reports state that ^99m^Tc-MIBI SMM always showed a low sensitivity for detecting DCIS. Vassilios Papantoniou et al. [@pone.0108349-Papantoniou1] studied the diagnostic accuracy of ^99m^Tc-MIBI SMM in 13 cases of DCIS and achieved a low sensitivity of 46%. Reinhard Obwegeser et al. [@pone.0108349-Brem1] reported that ^99m^Tc-MIBI SMM could not detect all four DCIS in their study. They conceived it may be due to the histological type of DCIS, which is known to show a lower density of tumor cells per square unit than invasive ductal carcinomas. Conversely, experimental studies using in vivo assays have shown that breast carcinoma in situ may be antigenic [@pone.0108349-Obwegeser1]. Sections stained for endothelial markers have shown increased vascularity around DCIS [@pone.0108349-Weidner1]--[@pone.0108349-Schor1]. A more detailed study demonstrated two patterns of increased vascularity: cuffs of vessels close to the involved ducts and vessels diffusely arranged in the interductal stroma [@pone.0108349-Guidi1]. The true positive result with ^99m^Tc-3P~4~-RGD~2~ SMM in this common malignant tumor may be an advantage of RGD targeting. Further studies with a larger patient population is needed to determine this issue.

Three of the 11 patients with fibroadenoma showed focal ^99m^Tc-MIBI uptake, and one patient from this group who was diagnosed with fibroadenoma with severe mammitis on histopathological examination showed high focal tracer accumulation of ^99m^Tc-3P~4~-RGD~2~. The false positive results obtained with ^99m^Tc-MIBI in three fibroadenoma may be due to the high cellular activity associated in fibroadenoma. Previous studies have demonstrated that integrin αvβ3 is preferentially expressed on several types of cancer cells including melanoma, glioma, and ovarian and breast cancer. However, because expression is very low in existing blood vessels and absent in normal tissue, the accumulation of ^99m^Tc-3P~4~-RGD~2~ may be mainly due to its higher specificity [@pone.0108349-vanderFlier1]--[@pone.0108349-Kuwano1]. As is known to all, inflammation was different from other benign lesions, always showed high cell density and vascularity, likely responsible for the increased uptake. Previous studies have also shown that the integrin αvβ3 can exist on neutrophils, monocytes, and vascular smooth muscle cells [@pone.0108349-Horton1], which can be the main reason for the false positive result using ^99m^Tc-3P~4~-RGD~2~ SMM.

In conclusion, ^99m^Tc-3P~4~-RGD~2~ SMM does not provide any significant advantage over the established ^99m^Tc-MIBI SMM for differentiating breast lesions. The uptake of ^99m^Tc-3P~4~-RGD~2~ in breast cancer was higher than that of ^99m^Tc-MIBI. ^99m^Tc-3P~4~-RGD~2~ seems to be more accurate than ^99m^Tc-MIBI in the detection of DCIS and fibroadenoma. But with only a few patients, there was no statistically significant difference between ^99m^Tc-3P~4~-RGD~2~ and ^99m^Tc-MIBI SMM. Future studies will involve higher sample numbers.
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